Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 173-179 , July 1997

The clinical relevance of HTLV type I and II in transfusion medicine

  • Hans Vrielink

      Affiliations

    • Red Cross Blood Bank Amsterdam, Amsterdam, Holland
    • Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, Holland
    • Corresponding Author InformationAddress reprint requests to H. Vrielink, MD, PhD, Red Cross Blood Bank Amsterdam, PO Box 9137, 1006 AC Amsterdam, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
    • ,
  • Hans L. Zaaijer

      Affiliations

    • Red Cross Blood Bank Amsterdam, Amsterdam, Holland
    • Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, Holland
    • ,
  • Henk W. Reesink

      Affiliations

    • Red Cross Blood Bank Amsterdam, Amsterdam, Holland
    • Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, Holland

References 

  1. Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415–7419
  2. Shimotohno K, Takahashi Y, Shimizu N, et al. Complete nucleotide sequence of an infectious clone of human human T-cell leukemia virus type II: An open reading frame for the protease gene. Proc Natl Acad Sci USA. 1985;82:3101–3105
  3. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-lymphotropic virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1992;218:571–575
  4. Seiki M, Hattori S, Yoshida M. Human adult T-cell leukemia virus: Molecular cloning of the provirus DNA and the unique terminal structure. Proc Natl Acad Sci USA. 1982;79:6899–6902
  5. Meytes D, Schochat B, Lee H, et al. Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. Lancet. 1990;336:1533–1535
  6. Hjelle B. Human T-cell leukemia/lymphoma viruses. Life cycle, pathogenicity, epidemiology and diagnosis. Arch Pathol Lab Med. 1991;151:440–450
  7. Kazura JW, Saxinger WC, Wenger J, et al. Epidemiology of human T cell leukemia virus type I infection in East Sepik province, Papua New Guinea. J Inf Dis. 1987;155:1100–1107
  8. Yanagihara R, Ajdukiewicz AB, Garruto RM, et al. Human T-lymphotropic virus type I infection in the Solomon Islands. Am J Trop Med Hyg. 1991;44:122–130
  9. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet. 1991;337:1435–1439
  10. Feigenbaum F, Fang C, Sandler SG. Human T-lymphotropic virus type-II in Panamanian Guaymi Indians. Transfusion. 1994;34:158–161
  11. Maloney EM, Biggar RJ, Neel JV, et al. Endemic human T-cell lymphotropic virus type-II infection among isolated Brazilian Amerindians. J Inf Dis. 1992;166:100–107
  12. Gessain A, Fretz C, Koulibaly M, et al. Evidence of HTLV-II infection in Guinea, West Africa. J Acq Immune Defic Synd and Hum Retrov. 1993;6:324–325
  13. Madeleine MM, Wiktor SZ, Goedert JJ, et al. HTLV-I and HTLV-II world-wide distribution: reanalysis of 4,832 immunoblot results. Int J Cancer. 1993;54:255–260
  14. Vrielink H, Sisay Y, Reesink HW, et al. Evaluation of a combined lysate/recombinant antigen anti-HTLV-I/II ELISA in high and low endemic areas of HTLV-I/II infection. Transfus Med. 1995;5:135–137
  15. (suppl) Hall WW, Ishak R, Zhu SW, et al. Human T Lymphotropic Virus Type II (HTLV-II): Epidemiology, Molecular Properties, and Clinical Features of Infection. J Acq Immune Defic Synd and Hum Retrov. 1996;13:S204–S214
  16. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang. 1994;46:245–253
  17. Centers for Disease Control and Prevention  USPHS Working Group. Guidelines for counselling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann Int Med. 1993;118:448–454
  18. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer. 1992;51:886–891
  19. Richardson JH, Edwards AJ, Cruickshank JK, et al. In vivo cellular tropism of human T-cell leukemia virus type I. J Virol. 1990;64:5682–5687
  20. Inaba S, Sato H, Okochi K, et al. Prevention of transmission of human T-lymphotropic virus type I (HTLV-I) through transfusion, by donor screening with antibody to the virus. Transfusion. 1989;29:7–11
  21. Kusuhara K, Sonoda S, Takahashi K, et al. Mother-to-child transmission of human T-cell leukemia virus type I (HTLV-I): a fifteen-year follow-up in Okinawa, Japan. Int J Cancer. 1987;40:755–757
  22. (suppl) Hino S, Katamine S, Miyata H, et al. Primary prevention of HTLV-I in Japan. J Acq Immune Defic Synd and Hum Retrov. 1996;13:S199–S203
  23. Manns A, Blattner WA. The epidemiology of the human T-cell lymphotropic virus type I and type II: Etiologic role in human disease. Transfusion. 1991;31:67–75
  24. Takatsuki K, Uchiyama T, Sagawa K, et al. Adult T-cell leukemia in Japan. In: Topics in hematology. Amsterdam: Excerpta Medica; 1977;p. 73–77
  25. Seiki M, Eddy R, Shows TB. Non-specific integration of the HTLV provirus into adult T-cell leukemia cells. Nature. 1984;309:640–642
  26. Murphy EL, Hanchard R, Figueroa JP, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type-I. Int J Cancer. 1989;43:250–253
  27. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–492
  28. (suppl) Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. J Acq Immune Defic Synd and Hum Retrov. 1996;13:S15–S19
  29. (abstr, suppl) Murphy EL, Friday J, Smith JW, et al. High prevalence of HTLV-associated myelopathy (HAM) among subjects infected with HTLV-I and -II. Transfusion. 1993;33:S263
  30. Gessain A, Gout O. Chronic myelopathy associated with Human T-Lymphotropic Virus Type I (HTLV-I). Ann Int Med. 1992;117:933–946
  31. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med. 1990;322:383–388
  32. Anderson DW, Epstein JS, Lairmore MD, et al. Serological confirmation of human T-cell lymphotropic virus type I infection in healthy blood and plasma donors. Blood. 1989;74:2585–2591
  33. Dodd RY. Adverse consequences of blood transfusion: quantitative estimates. In: Nance ST editors. Blood supply: risks, perceptions and prospects for the future. Bethesda, MD: American Association of blood banks; 1994;p. 1–24
  34. (suppl) Jacobson S. Cellular immune response to HTLV-I: Immunopathogenic role in HTLV-I associated neurologic disease. J Acq Immune Defic Synd and Hum Retrov. 1996;13:S100–S106
  35. Kira J-I, Koyanagi Y, Hamakado T, et al. HTLV-II in patients with HTLV-I associated myelopathy. Lancet. 1991;338:64–65
  36. Hjelle B, Appenzeller O, Mills R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet. 1992;339:645–646
  37. Murphy EL, Engstom JW, Miller K, et al. HTLV-II associated myelopathy in 43-year-old woman. Lancet. 1993;341:757–758
  38. Wiktor SZ, Pate EJ, Weiss SH, et al. Sensitivity of HTLV-I antibody assays for HTLV-II. Lancet. 1991;338:512
  39. Hjelle B, Wilson C, Cyrus S, et al. Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors. Blood. 1993;81:1641–1644
  40. (abstr, suppl) Rios M, Khabbaz RF, Kaplan JE, et al. Transmission of HTLV-II by HTLV-I screened blood products. Transfusion. 1993;33:S260
  41. North ML, Lemaire JM, Couroucé JAM, et al. Performance of kits for the detection of anti-HTLV-I/II antibodies commercialized in France in 1995. J Acq Immune Defic Synd and Hum Retrov. 1995;10:254
  42. Vrielink H, Reesink HW, Zaaijer HL, et al. Sensitivity and specificity of four anti-human T-cell lymphotropic virus type I or type I/II assays. Transfusion. 1996;36:344–347
  43. Lipka JJ, Santiago P, Chan L, et al. Modified Western blot assay for confirmation and differentiation of human T-cell lymphotropic viruses type I and II. J Infect Dis. 1991;164:400–403
  44. Roberts BD, Foung SKH, Lipka JJ, et al. Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic viruses types I and II. J Clin Microbiol. 1993;31:260–264
  45. Brodine SK, Kaime EM, Roberts C, et al. Simultaneous confirmation and differentiation of human T-lymphotropic viruses types I and II infection by modified Western blot containing recombinant envelope glycoproteins. Transfusion. 1993;33:925–929
  46. Zaaijer HL, Cuypers HTM, Dudok de Wit C, et al. Results of 1-year screening of donors in The Netherlands for human T-lymphotropic virus (HTLV) type I: significance of Western, blot patterns for confirmation of HTLV infection. Transfusion. 1994;34:877–880
  47. Andersson S, Tynell E, Lithander E, et al. Results of a one year screening of Swedish blood donors for HTLV. J Acq Immune Defic Synd and Hum Retrov. 1995;10:251
  48. Christiansen CB. Experience with one year of blood donor screening for HTLV-I/II in Denmark. J Acq Immune Defic Synd and Hum Retrov. 1995;10:251
  49. Leite F, Mota AP, Monteiro R, et al. The interpretation of human T leukemia virus indeterminate Western blot patterns. J Acq Immune Defic Synd and Hum Retrov. 1995;10:254
  50. (abstr, suppl) Tegtmeier G, Henderson S, Polito A, et al. Supplemental testing of anti-HTLV-I EIA-reactive blood donor samples using RIBA strip immunoassay (SIA). Transfusion. 1995;35:S196
  51. Vrielink H, Zaaijer HL, Van der Poel CL, et al. New strip immunoblot for confirmation of HTLV-I/II infection. Vox Sang. 1996;70:114–116
  52. Levine PH, Blattner WA, Clark J, et al. Geographic distribution of HTLV-I and identification of a new high-risk population. Int J Cancer. 1988;42:7–12
  53. Garin B, Gosselin S, de Thé G, et al. HTLV-I/II infection in a high viral endemic area of Zaire, Central Africa: Comparative evaluation of serology, PCR, and significance of indeterminate Western blot pattern. J Med Virol. 1994;44:104–109
  54. Zaaijer HL, Cuypers HTM, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993;341:722–724
  55. Noordhoek GT, Kolk AHJ, Bjune G, et al. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: A blind comparison study among seven laboratories. J Clin Microbiol. 1994;32:277–284
  56. Quint WGV, Heijtink RA, Schirm J, et al. Reliability of hepatitis B virus DNA detection. J Clin Microbiol. 1995;33:225–228
  57. Damen M, Cuypers HTM, Zaaijer HL, et al. International collaborative study on the second Eurohep HCV-RNA reference panel. J Virol Methods. 1996;58:175–185
  58. Vrielink H, Zaaijer HTM, Cuypers HTM, et al. Evaluation of a new HTLV-I/II polymerase chain reaction. Vox Sang. 1997;72:144–147
  59. Osame M, Janssen R, Kubota H, et al. Nationwide survey of HTLV-I associated myelopathy in Japan: Association with blood transfusion. Ann Neurol. 1990;25:50–56
  60. Nelson KE, Donahue JG, Munoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery; a multicenter study of HIV-1, and HTLV-I/II infections. Ann Intern Med. 1992;117:554–559
  61. The HTLV European Research Network . Seroepidemiology of the human T-cell leukaemia/lymphoma viruses in Europa. J Acq Immune Defic Synd and Hum Retrov. 1996;13:68–77
  62. Couroucé A-M, Pillonel J, Lemaire J-M, et al. HTLV-I and HTLV-II infections in French blood donors. Vox Sand. 1993;65:334
  63. Vrielink H, Van der Poel CL, Reesink HW. Efficacy of selected versus random blood donor screening for anti-HTLV-I antibodies. Vox Sang. 1995;68:251–252
  64. Pillonel J, Couroucé AM, Lemaire JM. HTLV-I/II infection among French blood donors. J Acq Immune Defic Synd and Hum Retrov. 1995;10:251
  65. Soriano V, Vallejo A, Gutiérrez M, et al. Epidemiology of HTLV-I/II infections in Spain. J Acq Immune Defic Synd and Hum Retrov. 1985;10:251

PII: S0887-7963(97)80038-7

doi: 10.1053/tmrv.1997.0110173

Transfusion Medicine Reviews
Volume 11, Issue 3 , Pages 173-179 , July 1997

Article Tools